Deutsche Bank maintained its sell rating and 11,500p price target on AstraZeneca shares despite positive phase III trial results presented at the ASCO 2026 conference. The EMERALD-3 trial showed a 30% reduction in disease progression risk for a liver cancer immunotherapy combo, but regulatory approval remains uncertain. The bank also highlighted concerns about AstraZeneca's breast cancer drug camizestrant and noted the absence of AstraZeneca from ASCO's plenary session for the first time since 2018. Looking ahead, 2027 could bring key pipeline catalysts with several phase III readouts expected, while early sales of the new hypertension drug Baxfendy have been mixed.
Deutsche Bank maintains a sell rating on AstraZeneca with a price target of 11,500p, despite shares trading at 13,064p. The bank views the recent ASCO conference data, including the positive phase III EMERALD-3 trial for liver cancer, as incremental ...
AstraZeneca reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor significantly improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer. The treatment ...
AstraZeneca's Phase 3 EMERALD-3 trial demonstrated that the STRIDE regimen, combining immunotherapy drugs Imfinzi and Imjudo with lenvatinib and TACE, significantly improved progression-free survival by 30% compared to TACE alone in patients with unr...
At ASCO 2026, European pharma firms had a quiet showing, but AstraZeneca and Roche faced key challenges. AstraZeneca's lung cancer drug Datroway competes with Merck's sac-TMT, which showed strong efficacy but high toxicity, making AstraZeneca's bioma...
